← Back to trade feed
ABT Buy
Thomas KeanRepublican · NJ-7 · HouseTraded Jul 21, 2025Notified Aug 1, 2025
Trade details
| Amount | $1,001 – $15,000 |
| Asset | Abbott Laboratories Common Stock (ABT) [ST] (ST) |
| Issuer | ABBOTT LABORATORIES |
| Disclosure | 2025 PTR |
What happened next
Stock performance after the trade and after the disclosure became public, compared with SPY, an S&P 500 ETF.
Historical market data is not connected yet.
Conflict Score
65
Direct jurisdiction
Committee–industry overlap. The explanation and original filing are available below.
Why this score
- Rep. Thomas Kean (R-NJ) sits on the HSIF, whose jurisdiction covers: health, pharma.
- ABBOTT LABORATORIES (SIC 2834: Pharmaceutical Preparations) maps to the health, pharma domains, placing it under that committee's direct oversight.
Powered by the base rules engine. Modifiers (trade size, timing, owner, options) are layered in a later release.
What do the scores mean? Committee–industry overlap
- 65
- Direct jurisdiction
- 50
- Subcommittee
- 30
- Sector overlap
- 18
- Broad jurisdiction
- 0
- No mapped overlap
- —
- Not scored · missing data
The current base model tops out at 65 on a reserved 0–100 scale. Scores are not probabilities or findings of wrongdoing. Zero means no overlap in our mapping, not an absence of all possible conflicts. Read the methodology →
Original extracted asset text
Amount Cap. Gains > Abbott Laboratories Common Stock (ABT) [ST]
Extraction may include form headers. The linked original filing is authoritative.